180 Life Sciences (ATNF) announced that it has entered into a securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct ...
Zacks Investment Research on MSN
Is T Rowe Price Science & Technology Fund (PRSCX) a strong mutual fund pick right now?
If you've been stuck searching for Sector - Tech funds, consider T. Rowe Price Science & Technology Fund (PRSCX) as a possibility. PRSCX bears a Zacks Mutual Fund Rank of 1 (Strong Buy), which is ...
CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling ...
Sight Sciences, Inc.'s share price has fallen by -13.3% in the past 3 weeks, despite reporting a narrower-than-expected net loss in Q1 and sticking to its 2023 guidance. Sight Sciences' key Q1 2023 ...
BTIG analyst Mark Massaro lowered the firm’s price target on Exact Sciences (EXAS) to $65 from $82 and keeps a Buy rating on the shares. The company delivered a Q3 revenue miss and large guide-down, ...
Piper Sandler analyst David Westenberg lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $85 following quarterly results. The firm keeps an Overweight rating on the shares.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results